United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Wellcome today announced the launch of the Surveillance Partnership to Improve Data for Action on Antimicrobial Resistance (SPIDAAR), a new multi-year, public-private research collaboration with the governments of Ghana, Kenya, Malawi and Uganda to track resistance patterns and better understand the burden of antimicrobial resistance (AMR) on patients living in low- and middle-income countries. This first-of-its kind partnership will provid

Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa

The drugmaker offers a dividend yield of almost 4.5%.

The Promise and Perils of Owning Pfizer

Pfizer (PFE) begins four phase III studies on vaccine candidates. EMA validates its label expansion application for Bavencio in first-line bladder cancer.

Pfizer Begins Four Phase III Studies on Vaccine Candidates

Chevron

Dow Inc

JPMorgan Chase & Co

Coca-Cola

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Walgreens

Exxon Mobil

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration."

Dogs Of The Dow For June: 3 To Adopt, 1 To Ignore

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the initiation of four Phase 3 clinical trials within its current pipeline of investigational vaccines: Two studies (NCT04382326 and NCT04379713) of the 20-valent pneumococcal polysaccharide conjugate vaccine candidate, 20vPnC, evaluating a four-dose series in infants starting at 2 months of age. Both studies will expand the data on the safety and tolerability of the investigational vaccine in infants and include a control group

Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines

Arrow Financial

Dominion Energy

Diageo

DTE Energy

Duke Energy

Con Ed

Intercontinental Exchange

Altria

People's United Financial

PepsiCo

Pinnacle West Capital

Southwest Gas Hlds

AT&T

TC Energy

Travelers

Volatility has returned to the market due to the highest market valuations in 19 years, combined with concerns about rising US COVID-19 cases and skepticism about a V-shaped recovery.

17 Low-Volatility Blue-Chips You Can Safely Buy During These Dangerous Times

AstraZeneca

GlaxoSmithKline

Johnson & Johnson

Moderna

Novavax

Globally, there are more than 100 vaccines under development - with nine of them in human clinical trials already.

Who's Ahead In Finding A COVID-19 Vaccine?

Mylan

Sanofi

Hydroxychloroquine as a COVID-19 treatment has been a controversial subject -- and the debate continues.

Is Hydroxychloroquine a Cure for COVID-19?

Sangamo Therapeutics

While the data looks good so far, the duo's treatment is behind a similar BioMarin therapy in the testing and approval process.

Pfizer and Sangamo's Gene Therapy Continues to Help Patients with Hemophilia in Clinical Trial

If you're looking for growth, go ahead and ignore Pfizer stock. For dividend and income investors though, let's evaluate PFE stock.

Time to Bail on Pfizer? Let’s Look at the Charts

Merck

Only one of these two pharma titans has a history of growth.

Better Buy: Pfizer vs. Merck

Home Depot

McDonald's

Are you wondering which Dow Jones companies to buy right now? Let's take a closer look at three top names that could belong in a long-term portfolio.

3 Dow Jones Companies to Buy When Profit-Taking Kicks In

BioNTech SE

Emergent BioSolutions

Globally, there are more than 100 vaccines under development — with nine of them in human clinical trials already, asserts equity analyst Sel Hardy, in CFRA Research's flagship newsletter, The Outlook.

9 Pharmaceutical Companies Racing For A COVID-19 Vaccine

Inovio Pharmaceuticals

Some of the earliest novel coronavirus (COVID-19) vaccines to be approved are more likely to target prevention against developing severe symptoms from catching the virus, rather than the initial infection, multiple health experts told Bloomberg.

Early Coronavirus Vaccines Likely To Target Further Complications, Not Infection, Health Experts Say

Pfizer's (PFE) investigational eczema treatment, abrocitinib, succeeds in a late-stage study under the JADE program in patients aged 12 years and above.

Pfizer's Eczema Candidate Meets All Goals in Study on Teens

Cisco Systems

Intel

Microsoft

It takes a certain kind of courage to short sell blue chips, such as the Dow Jones industrial average components.

The 5 Most Shorted Dow Stocks (June 10)

Goldman Sachs

Pfizer Inc. (PFE) CEO Albert Bourla Presents at Goldman Sachs 41st Annual Global Healthcare Conference (Transcript)

Apple

Biogen

Micron Technology

Insider trades are one of the most-discussed stock market topics out there. Unfortunately, there's a lack of knowledge about insider returns.

Insider Outperformance: Key Takeaways And How To Benefit Significantly From It

News for Pfizer Stock (PFE)